Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …

Advances in biomarkers, targeted therapies, and immuno-oncology have transformed the
clinical management of patients with advanced NSCLC. For oncogene-driven tumors, there …

Activating mutations in the epidermal growth factor receptor gene occur as early cancer-
driving clonal events in a subset of patients with non-small cell lung cancer (NSCLC) and …

EGFR mutations account for the majority of druggable targets in lung adenocarcinoma. Over
the past decades the optimization of EGFR inhibitors revolutionized the treatment options for …

Simple Summary Osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor, is currently indicated as first-line therapy in patients with non-small …

Simple Summary Resistance to tyrosine kinase inhibitors (TKIs) of the epidermal growth
factor receptor (EGFR) in advanced mutant non-small cell lung cancer (NSCLC) constitutes …

Highlights•Acquired resistance mechanisms to osimertinib can be EGFR dependent or
independent.•First-and fourth-generation EGFR-TKIs are able to overcome EGFR …

Mutations in the epidermal growth factor receptor (EGFR) gene are the most common
targetable genomic drivers of non-small cell lung cancer (NSCLC), occurring in …

Purpose: Resistance to third-generation EGFR inhibitors including osimertinib arises in part
from the C797S mutation in EGFR. Currently, no targeted treatment option is available for …

Osimertinib, a mutant-specific third-generation EGFR tyrosine kinase inhibitor, is emerging
as the preferred first-line therapy for EGFR-mutant lung cancer, yet resistance inevitably …